The Role of Small Interfering RNAs in Hepatocellular Carcinoma

Chen, Feng; Zhang, Wang; Gao, Xinran; Yuan, Hui; Liu, Kehai

doi:10.1007/s12029-023-00911-w

Cited by 1 publication

(1 citation statement)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2–4 Because of the various etiologies and accumulation of genetic changes in HCC, it is a type of heterogeneous cancer, which makes treatment difficult. 5 Surgical, systemic, locoregional, and other potential therapies have been used for the treatment of HCC, and many studies are currently underway. 6 , 7 However, measures have been taken to improve the prognosis of patients with HCC, and the recurrence and mortality rates are still high.…”

Section: Introductionmentioning

confidence: 99%

Transarterial Chemoembolization Plus Sorafenib versus Transarterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma: An Umbrella Review of Meta-Analyses and Systematic Reviews

Yan,

Wen,

Deng

et al. 2023

JHC

View full text Add to dashboard Cite

Background Sorafenib is the standard treatment for most cases of advanced hepatocellular carcinoma (HCC), based on Western and Eastern clinical guidelines. Thus, an increasing number of transarterial chemoembolization (TACE) plus sorafenib combination therapies have been used in clinical practice. In addition, several systematic reviews and meta-analyses have explored the efficacy and safety of the combination of TACE and sorafenib. Therefore, we performed an umbrella review to summarize and evaluate these evidence-based studies. Methods PubMed, Embase, Cochrane Library, and Web of Science databases were searched up to June 1, 2023. All meta-analyses that evaluated the effect of TACE plus sorafenib on HCC were considered eligible. The quality of the included meta-analyses was evaluated by AMSTAR2 (A Measurement Tool to Assess Systematic Reviews). The quality of evidence per association provided in the meta-analyses was rated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE). This study was registered with PROSPERO (Registration ID: CRD42023420417). Results We included 12 meta-analyses, including randomized clinical trials, cohort studies, and observational studies. A total of 44 associations with overall survival, survival rate, time to disease progression, overall response rate, disease control rate, and adverse events were evaluated in this umbrella review. The quality of most associations ranged from low to very low, indicating that flaws were significant in the current meta-analyses. Conclusion This umbrella review identified beneficial associations between TACE and sorafenib combination therapy in advanced HCC. However, owing to the low certainty of the evidence, clinicians should interpret our results with caution when applying them in clinical practice, and high-quality studies are required in the future to confirm our results.

show abstract